Legend Biotech (LEGN) Income towards Parent Company (2019 - 2026)
Legend Biotech's (LEGN) quarterly Income towards Parent Company came in at -$55.0 million in Q1 2026, up 45.5% YoY from -$37.8 million in Q1 2025, and down 77.99% on a QoQ basis from -$30.9 million in Q4 2025.
Legend Biotech (LEGN) Income towards Parent Company (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Income towards Parent Company data on file, last reported at -$55.0 million in Q1 2026.
- Quarterly Income towards Parent Company rose 45.5% year-over-year to -$55.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$248.6 million (down 1.7% YoY) and the FY2025 annual result came in at -$296.8 million, down 167558.99% from the prior year.
- Income towards Parent Company fell to -$55.0 million in Q1 2026, from -$30.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $26284.0 in Q4 2024 to a low of -$199.1 million in Q2 2023.
- A 5-year average of -$80.7 million and a median of -$62.2 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2024 — Income towards Parent Company soared 118.15% — and 2025, when it plunged 117662.01%.
- Tracing LEGN's Income towards Parent Company over 5 years: stood at -$135.9 million in 2022, then surged by 99.89% to -$144818.0 in 2023, then jumped by 118.15% to $26284.0 in 2024, then sank by 117662.01% to -$30.9 million in 2025, then plunged by 77.99% to -$55.0 million in 2026.
- The last three Income towards Parent Company figures came in at -$55.0 million (Q1 2026), -$30.9 million (Q4 2025), and -$38.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.20 Mn |
| Mar 31, 2026 | -55.00 Mn |
| Dec 31, 2025 | -30.90 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.22 Mn |
| Mar 31, 2025 | -100.92 Mn |
| Dec 31, 2024 | 26,284.00 |
| Sep 30, 2024 | -125.32 Mn |
| Jun 30, 2024 | -18.20 Mn |
| Mar 31, 2024 | -59.79 Mn |
| Dec 31, 2023 | -144,818.00 |
| Sep 30, 2023 | -62.21 Mn |
| Jun 30, 2023 | -199.13 Mn |
| Mar 31, 2023 | -112.10 Mn |
| Dec 31, 2022 | -135.88 Mn |
| Sep 30, 2022 | -84.96 Mn |
| Jun 30, 2022 | -193.23 Mn |
| Mar 31, 2022 | -32.29 Mn |
| Dec 31, 2021 | -88.33 Mn |
| Sep 30, 2021 | -124.75 Mn |